文献类型：期刊文献

英文题名：Dual "Unlocking" Strategy to Overcome Inefficient Nanomedicine Delivery and Tumor Hypoxia for Enhanced Photodynamic-Immunotherapy

作者：Li, Xianglong[1];Jiang, Cong[2];Jia, Xinlin[3];Cao, Yuanyuan[1];Mao, Yuanqing[3];Hao, Ji-Na[1];Yang, Yang[2];Zhang, Peng[2];Li, Yongsheng[1]

机构：[1]East China Univ Sci & Technol, Frontier Sci Ctr Mat Biol & Dynam Chem, Shanghai Engn Res Ctr Hierarch Nanomat, Sch Mat Sci & Engn,Lab Low Dimens Mat Chem,Key Lab, Shanghai 200237, Peoples R China;[2]Tongji Univ, Shanghai Pulm Hosp, Dept Thorac Surg, Sch Med, Shanghai 200092, Peoples R China;[3]Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Orthopaed Surg, Shanghai Key Lab Orthopaed Implants,Sch Med, Shanghai 200011, Peoples R China

年份：2023

卷号：12

期号：6

外文期刊名：ADVANCED HEALTHCARE MATERIALS

收录：;EI(收录号：20224813196266);WOS:【SCI-EXPANDED(收录号:WOS:000891157500001)】；

基金：X.L. and C.J. contributed equally to this work. This work was financially supported by the National Natural Science Foundation of China (Nos. 51621002, 51972112, 52172279, 21805087, and 81972172), Basic Research Program of Shanghai (21JC1406003 and 19JC1411700), Leading Talents in Shanghai in 2018, Program of Shanghai Academic/Technology Research Leader (19XD1423200), Shanghai Rising Star Program (21QA1402200), the Natural Science Foundation of Shanghai (21ZR1416600), the 111 project (B14018), and Programs of Shanghai Pulmonary Hospital (FKCX1904). Animal experiments were executed according to the protocol approved by the Laboratory Animal Management Committee of East China University of Science and Technology (approval number: ECUST-2020-04001).

语种：英文

外文关键词：anti-programmed death-ligand 1; immunotherapy; nanomedicine delivery; photodynamic therapy; tumor micro-vessel density modulation

摘要：Lacking blood vessels is one of the main characteristics of most solid tumors due to their rapid and unrestricted growth, which thus causes the inefficient delivery efficiency of nanomedicine and tumor hypoxia. Herein, a dual "unlocking" strategy to overcome these obstacles is proposed by combining engineered hybrid nanoparticles (named ZnPc@FOM-Pt) with dexamethasone (DXM). It is verified that pretreatment of tumors with DXM can increase intratumorally micro-vessel density (delivery "unlocking") to enhance the tumor delivery efficiency of ZnPc@FOM-Pt and decrease HIF-1 alpha expression. Correspondingly, more Pt can catalyze tumor-overexpressed H2O2 to produce oxygen to further cause hypoxia "unlocking," ultimately achieving boosted ZnPc-based photodynamic therapy in vivo (tumor inhibition rate: 99.1%). Moreover, the immunosuppressive tumor microenvironment is efficiently reversed and the therapeutic effect of anti-PD-L1-based immunotherapy is promoted by this newly designed nanomedicine. This dual "unlocking" strategy provides an innovative paradigm on simultaneously enhancing nanomedicine delivery efficacy and hypoxia relief for tumor therapy.